Skip to main content

Table 2 Baseline and intra-/posttherapeutic hematologic toxicity grades based on CTCAE v5.0

From: Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

 

Baseline (%)

Intra-/posttherapeutic (%)

Grade 1

Grade 2

Grade 3

Grade 4

Grade 1

Grade 2

Grade 3

Grade 4

Anemia

85 (61)

24 (17)

2 (1)

0 (0)

77 (55)

42 (30)

10 (7)

0 (0)

Leukopenia

10 (7)

3 (2)

0 (0)

0 (0)

27 (19)

11 (8)

5 (4)

0 (0)

Thrombocytopenia

13 (9)

2 (1)

0 (0)

0 (0)

39 (28)

3 (2)

5 (4)

1 (1)